Press Room

Latest

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

2001


News - 2017

Uscom BP+ Distributor for SE Asia

July 17th, 2017

Appointment of established partner to distribute BP+ and BP+ Reporter in South East Asia

Uscom has announced a distribution agreement for the Uscom BP+ and BP+ Reporter with Pacific Medical Systems Limited (PMS) of Hong Kong. The three year agreement covers distribution into Thailand, Hong Kong and Macau, Singapore, Taiwan, Malaysia and Indonesia

Key Points

Executive Chairman of Uscom, Associate Professor Rob Phillips said, “This is another major territory covered by new distributors preparing to deliver the innovative Uscom BP+ and BP+ Reporter to market. PMS are experienced master distributors in China and SE Asia and are keen to get sales under way as soon as regional regulations allows. Worldwide we are appointing new distribution to ensure that immediately our regulatory approvals are received we can begin to sell these revolutionary technologies in the market. The patent protected BP+ devices have major application for assessment of hypertension and vascular health, rapidly increasing disease with high social and cost burdens.”

Uscom manufactures and markets the USCOM 1A, the Uscom BP+, and the Uscom SpiroSonic digital ultrasonic spirometry technologies. These premium digital devices are changing the way we diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD and sleep disorders. The products are integral for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, and in clinical and home care delivered asthma and COPD medications and in sleep medicine.

TGA for Uscom SpiroSonic Digital Spirometers

July 13th, 2017

Uscom advanced digital ultrasonic SpiroSonic lung function devices receive regulatory listing for sale in Australia

Uscom announced that the Uscom SpiroSonic product range of lung function monitors have been listed on the Australian Regulator of Therapeutic Goods (ARTG) by the Therapeutic Goods Administration (TGA). This listing allows sale of the Uscom high fidelity, digital ultrasonic SpiroSonic pulmonary function monitors as a class IIA device.

Key Points

Regulatory approvals are essential for permission to sell in almost all global jurisdictions and are evaluated in terms of safety and efficacy. The SpiroSonic devices are listed by the ARTG with the identifier 291176. The SpiroSonic devices already have CE (Europe) and now TGA approval, and are in process for CFDA (China) and FDA (USA). The Uscom BP+ and BP+ Reporter are also undergoing the same processes, but because of precedent approvals the timeline may be shorter. However the duration of the regulatory processes vary with jurisdiction and product, and are therefore uncertain. Uscom has already appointed an Australian distributor to begin sales, and multiple new European distributors, and is looking to appoint new US and SE Asian distributors.

Executive Chairman of Uscom, Associate Professor Rob Phillips said, “Regulatory approval is the path to sales and revenue for our new products, and each new approval represents another regional revenue stream. Our strategic objective is to bring the SpiroSonic devices and the BP+ central blood pressure devices to global markets and anticipate receiving regulatory approvals for all products in all jurisdictions intermittently over the next 12mths. Our current growth has been predominantly attributable to USCOM 1A sales, and so the approval for sale of additional devices in additional jurisdictions represents incremental future revenue opportunities and growth drivers. We are building a real company aiming to combine blue sky, practice changing science with hard measures of sales, revenue, profitability and shareholder distributions. Regulatory approvals are vital steps in this process and a key focus of our operations.”

Uscom SpiroSonic Devices for Spanish Health Project

June 1st, 2017

Spanish eHealth monitoring of patients with chronic disease using digital Uscom SpiroSonic spirometers and software platform

Uscom subsidiary Uscom Europe announced a partnership with Sonmedica S.A., the Public Health Agency of Catalonia and the Health Campus of the University of Barcelona to deliver telemetric pulmonary care via the Nextcare Digital Health Care Project to patients in Catalonia. The project, the first of its kind worldwide, aims to deliver personalised home care to patients with chronic disease via a public digital health care framework.

The pulmonary arm of the Nextcare project is being led by Professor Josep Roca, MD, PhD, the Director of The Lung Function Unit at the Barcelona Hospital Clinic, Professor of Medicine at The University of Barcelona, and the former president of the European Respiratory Society credited with over 470 peer reviewed publications.

The pulmonary arm of the Nextcare project uses the new Uscom SpiroSonic tSpiro telemetric ultrasonic spirometers for the home care monitoring of patients with chronic pulmonary disease. The Uscom SpiroSonic devices utilise multi-path ultrasonic technology and are wirelessly connected to the central hospital record keeping systems with Uscom SpiroReporter proprietary digital phone and cloud based software applications. Specialist pulmonologists then evaluate the measurements and direct management via mobile phone, thus by-passing expensive hospital treatment.

Key Points

Uscom’s Global Head of Product Innovation and Digital Pulmonary Devices, George Ferenczi said: “Our engineering team have spent a lot of time working with Sonmedica and the scientists in the Nextcare program at the University of Barcelona matching the digital interfaces of our SpiroSonic devices with the Catalonian Hospital medical records systems and ensuring ease of digital communication and simplification of signal analysis.”

Executive Chairman of Uscom, Associate Professor Rob Phillips said: “Our digital health work with the Barcelona University and Public Health Agency of Catalonia is the first of its kind worldwide, and will become the template for digital health care worldwide; this project is setting the standards for eHealth excellence for the future. It’s a great credit to our Uscom engineers that this innovative model has been so seamlessly implemented for the benefit of the people of this highly developed region of Spain, and we look forward to the adoption of our digital technologies in similar models worldwide.”

Digital cloud based pulmonary monitoring is an emerging global trend in clinical care, and provides for early detection of changes in pulmonary function and improved guidance of therapy. This collaboration between the Public Health Agency of Catalonia, the Health Campus of the University of Barcelona, and Sonmedica with Uscom Europe is supported by European Union funding, and is further recognition of the superior quality of the SpiroSonic digital spirometers and our connectivity solutions. While many current spirometers use mechanical turbines, Uscom’s patented multi-path ultrasonic spirometers provide higher accuracy, lower maintenance, are simpler to use, and are more hygienic.

Uscom manufactures and markets the USCOM 1A, the Uscom BP+, and the Uscom SpiroSonic digital ultrasonic spirometry technologies. These premium digital devices are changing the way we diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD and sleep disorders. The products are integral for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, and in clinical and home care delivered asthma and COPD medications.

References:

http://blog.aquas.cat/wp-content/uploads/2016/12/Catalunya-2016-Reference-Sites.pdf

Uscom SpiroSonic Devices for French Lung Transplant Study

June 1st, 2017

Uscom has announced a partnership with French Company Aqsitania SAS to use the new Uscom SpiroSonic tSpiro telemetric pulmonary function devices for the monitoring and improved management of lung transplant patients. The tSpiro devices are advanced multi-path ultrasonic spirometers that connect wirelessly to personal communication devices, and ultimately web based software applications to monitor and analyse respiratory function allowing cost effective home care monitoring.

Key Points

Uscom’s Global Head of Digital Pulmonary Devices, George Ferenczi said, “Our new SpiroSonic tSpiro devices deliver research quality digital ultrasonic telemetric spirometry into the home care market, allowing specialist monitoring of pulmonary function in the patient’s home, providing more effective management and reducing expensive hospital attendances. Application of tSpiro for monitoring and guiding management of lung transplantation patients is new, and expands our established application in Asthma, COPD and Occupation Lung Disease.”

Executive Chairman of Uscom, Associate Professor Rob Phillips said, “Digital telemetric spirometry is the future of pulmonary medicine and we are at the forefront of this field. Aqsitania SAS is a world leader in pulmonary function signal analysis, and their algorithms depend on the highest quality spirometry sensors. We are delighted they are using Uscom tSpiro devices for their program to improve the care of lung transplants patients. We are already leaders in digital cloud based home care for asthma and COPD and Occupational Lung Disease Monitoring, and this is a further clinical application for our new SpiroSonic devices.”

Digital cloud based pulmonary monitoring is an emerging global trend in clinical care, and provides for early detection of changes in pulmonary function and improved guidance of therapy. This collaboration between Aqsitania SAS and Uscom Europe is supported by European Union funding is recognition of the superior quality of the SpiroSonic digital spirometers.

Uscom manufactures and markets the USCOM 1A, the Uscom BP+, and the Uscom SpiroSonic digital ultrasonic spirometry technologies. These premium digital devices are changing the way we diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD and sleep disorders. The products are integral for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, and in clinical and home care delivered asthma and COPD medications.

References:

http://www.aqsitania.com

Uscom boosts global sales and marketing

May 1st, 2017

New global Sales and Marketing Manager appointed to support release of new products.

Left to Right: Denise Pater, Damien Linnett and Rob Phillips

Uscom today announced the appointment of Damien Linnett to the position of Global Sales and Marketing Manager. Mr Linnett is an economics graduate from the University of Queensland, with an MBA in international marketing. He has over 20 years’ global medical device sales and marketing management experience.

Damien Linnett has previously held executive positions with international corporations Datex-Ohmeda and Spacelabs Healthcare, and most recently with Kinetic Concepts Inc. (KCI Medical), an Acelity Company. Mr Linnett joins the growing sales, marketing and distribution division of Uscom to accommodate and advance the increased product suites of Uscom devices.

Uscom has completed the development of the new BP+ and SpiroSonic devices and now has them in regulatory cycles, awaiting multiple jurisdiction approvals in China (CFDA), Europe (CE) and USA (FDA). The focus of the sales, marketing and distribution division will be to sign up new specialist distributors, manage the sale of the new devices, and grow the new revenue streams.

Mr Linnett said, “Uscom is a business in transformation as it approaches profitability with 7 new standard of care products due for imminent release to market. For me that represents an opportunity to accelerate global sales and revenue growth. Uscom has a growing international reputation as a corporation and manufacturer of premium medical devices with a great foundation product and rapidly growing market share. I’m looking forward to being a part of the Uscom growth story, and adding my skills to those of the current team to accelerate sales as we bring these new and exciting products to market.”

Uscom CEO Associate Professor Rob Phillips said, “Uscom sales have grown by over 60% CAGR over the last 3 years, we have acquired 2 companies, and are poised for the imminent release of 7 new products into the Chinese, European and US markets. We currently manage approximately 35 distributors globally and this number will grow, with 10 new distributors signed up and awaiting the release of the BP+ devices. Having someone of Damien’s outstanding capabilities and experience join our team to guide our new products into the market is ideal. Our continued growth requires experienced management and a strong and capable sales, marketing and distribution strategy, and Damien’s contribution to our global sales, marketing and distribution division will be central to Uscom’s future commercial success.”

Uscom manufactures and markets the USCOM 1A, the Uscom BP+, and the Uscom SpiroSonic digital ultrasonic spirometry technologies. These premium digital devices are changing the way we diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD and sleep disorders. The devices and technologies are integral for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, and in clinical and home care delivered asthma and COPD diagnosis and medication monitoring.

Uscom Achieves First Cash Flow Positive Quarter

April 19th, 2017

Appendix 4C

Record cash receipts – $1.41M (up 41%)
Record cash receipts from customers – $0.91M (up 43%)
Cash flow positive – $0.22M
Cash on hand – $2.13M

Uscom has achieved its first ever cash flow positive quarter in another record period for the Company. The results in the attached Appendix 4C – Quarterly cash flow report for the consolidated entity for the period ended 31 March 2017 (the Quarter) are in Australian dollars.

Highlights

For the Quarter, we note the following:

The Uscom 4C results for the quarter demonstrate record total cash receipts of $1.41M, up 41% on the corresponding prior Q3 ($1.00M), and record customer cash receipts of $0.91M, up 43% on the prior Q3 ($0.64M). Cash flow for the period was +$0.22M, up from the 2016 Q3 of -$0.06M. Cash on hand at the end of the period was $2.13M, up from $1.00M reported in 2016 Q3. An additional $1.2M in options remains outstanding at an exercise price of 25c and exercisable by 31st July 2017. An R&D tax refund of $0.50M was received during the current period, while $0.37M was received in the 2016 Q3.

Uscom CEO Associate Professor Rob Phillips said, “Our first cash flow positive quarter is especially satisfying as it comes on top of four consecutive years of 40%+ CAGR revenue growth. While both revenue and costs will continue to be lumpy, our strategy remains firmly focused on long term sustained revenue growth, profitability and, ultimately, shareholder dividends. During the quarter we have been completing the BP+, BP+ Reporter, SpiroSonic and SpiroReporter devices (seven products in all), and finalising regulatory submissions for approvals for their sale in the main jurisdictions of China, Europe and the USA. Once the devices are approved then a number of one off costs will be replaced by revenue. The devices are now all in regulatory cycles in all regions and we look forward to receiving the revenue growth that will flow once the approvals are received and our new and established distributor channels are activated. It is these supplementary revenue streams which we expect to accelerate our current growth over the coming years. We have invested wisely in acquisitions and new product development, and we are now poised for continuing and accelerated revenue growth.”

Uscom manufactures and markets the USCOM 1A, the Uscom BP+, and the Uscom SpiroSonic digital ultrasonic spirometry technologies. These premium digital devices are changing the way we diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD and sleep disorders. The devices and technologies are integral for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, and in clinical and home care delivered asthma and COPD diagnosis and medication monitoring.

New Uscom Euro Grant for Pulmonary Research

April 3rd, 2017

“Incentive based smart spacer to promote pulmonary recovery training & drug uptake”

Uscom has announced the award of a second European scientific research grant to Uscom Europe based in Budapest. Uscom was a member of a consortium awarded 1,317,502 Euro (≈AU$1.86) over 2 years to develop a new smart spacer and software to promote pulmonary recovery training and drug uptake under the Eurostars programme. The total value of the project is 1,317,502 Euro (AU$1.86) and Uscom will receive 349,480k Euro (≈AU$492k) over the next 2 years ($246k AUD pa).

Key Points

The project is titled “Incentive based smart spacer to promote pulmonary recovery training & drug uptake” (NEMZ_16-1-2017-0001) and focuses on the development of a new medical device that increases the efficiency of drug delivery from inhalation dispensers, supported by software to re-inforce the appropriate on going use of medication. Uscom’s advanced digital multi-path ultrasonic technology is already being adopted among cloud based telemetric pulmonary monitoring companies in the USA, while the sophisticated SpiroReporter archiving and analysis software which can be installed on smart phones, tablets, computers or the cloud provides opportunities to combine complex pulmonary function measurements with a remote digital monitoring platform.

While many new companies are marketing simple inhaler trackers connected to an app or software, the SpiroSonic tSpiro solution provides comprehensive pulmonary function monitoring of patients in their own home, with full cloud based telemetric analysis, diagnosis and management which generates “big data” for population disease profiling. Uscom’s contribution to this project is derived from experience in researching, developing and manufacturing world leading digital ultrasonic spirometers and digital respiratory monitoring technologies.

Executive Chairman of Uscom, Associate Professor Rob Phillips said, “Hundreds of millions of people around the world suffer from preventable chronic respiratory diseases, and this research funding focuses on solving a clinical problem that results in hundreds of thousands of deaths per year. This grant is recognition that Uscom has a global reputation for R&D and manufacturing of innovative cardiovascular and pulmonary monitoring devices, and the development of clinical solutions to drive improved global pulmonary care.”

Background:

The Eurostars programme is a joint programme by Eureka and the European Commission which is co-funded from the national budgets or 36 participating states and countries. The Hungarian National Research, Development and Innovation Office as part of the European Research Organisation administers the grant.

The entire grant project is a collaboration of Uscom Europe with a group of Dutch pulmonary specialists at Stichting Gelre Ziekenhuizen and SilverFit B.V. (The Dutch Foundation for the Elderly), and is planned to produce Uscom owned IP and products. This grant is in addition to the prior Hungarian grant of $427K AUD announced – Nov 28th 2016.

Uscom manufactures and markets the USCOM 1A, the Uscom BP+, and the Uscom SpiroSonic digital ultrasonic spirometry technologies. These premium digital devices are changing the way we diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD and sleep disorders. The devices and technologies are integral for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, and in clinical and home care delivered asthma and COPD diagnosis and medication monitoring.

References:

  1. https://ec.europa.eu/growth/tools-databases/regional-innovation-monitor/organisation/national-research-development-and-innovation-office.
  2. https://www.eurostars-eureka.eu/about-eurostars
  3. https://www.gelreziekenhuizen.nl/Gelreziekenhuizen
  4. http://silverfit.com/en/
  5. http://www.who.int/respiratory/copd/en/
  6. http://www.uscom.com.au/news/news.php?year=2016

New USCOM Evidence for Pre-eclampsia

March 30th, 2017

New evidence supports USCOM 1A screening and improved outcomes during pregnancy

Uscom has announced the publication of two new peer reviewed papers confirming the effectiveness of USCOM 1A for diagnosing pre-eclampsia and guiding hypertensive therapy in pregnancy. The publications were in the prestigious Ultrasound in Obstetrics and Gynaecology and authored by obstetrics and gynaecology specialists and researchers from the University of Rome, Rome, the Policlinico, Rome, and the St George’s Hospital, London.

Key Points

Professor Valensise and his team from the Department of Obstetrics and Gynaecology at the University of Rome Tor Vergata and Professor Khalil and her group at St George’s Hospital London have been using and researching the USCOM 1A in pregnancy for pre-eclampsia for over 3 years.

Executive Chairman of Uscom, Associate Professor Rob Phillips said, “Science is value for Uscom shareholders and this science provides us with a new revenue platform as our business continues rapid growth of the back of important scientific achievement. These data demonstrate that the use of USCOM in pregnancy can improve maternal and foetal outcomes in pregnancy, and support USCOM 1A use as a routine screening monitor of maternal hemodynamics, from the initial examination up to, and during, delivery and should be considered as a standard of care for monitoring pregnancy.”


Maternal health is an emerging USCOM 1A application with a number of leading centres globally researching pre-eclampsia using the USCOM 1A. These publications will support USCOM 1A adoption in this field and contribute to further growth of USCOM 1A revenues.

Study details
The first study, “Maternal cardiac output in early labour: a possible link with obstetrics risks?“, demonstrates that USCOM 1A measured changes in maternal circulation are associated with an 8-10 fold increased risk of maternal and foetal distress and maternal complications in otherwise low risk pregnant women. The study concluded that “(USCOM measures) can be used not only as a screening tool in the early identification of patients at high risk of hypertensive complications, but also in the evaluation of pregnancy at term in the absence of known risk factors,”

In the second study, “Nitric oxide (NO) donors and haemodynamic changes in fetal growth restriction”, 26 pregnant females with diagnosis of intrauterine growth restriction (IUGR) with 30 week gestational age foetuses, were enrolled. Their hemodynamics were monitored with USCOM 1A during treatment with transdermal nitric oxide donors (glycerine trinitrate). Nitric oxide acts on the placental to dilate the placental vessels and ensure adequate perfusion and oxygen supply to the growing foetus to ensure optimal development. The hemodynamics from these patients were then compared to an untreated, case matched, 26 patient cohort. The mothers with IUGR and NO donor treatment had significantly improved USCOM measured maternal hemodynamics, and had babies with significantly increased birth weight. The study concluded “……our results might open new perspectives in the treatment of fetal growth restriction, focusing on main maternal cardiovascular anomalies.”

References

  1. Valensise H, Tiralongo GM, Pisani D, Farsetti D, LoPresti D, Gagliardi G, Basile RM, Novelii GP, Vasapollo B. Maternal cardiac output in early labour: a possible link with obstetrics risks? Ultrasound Obstet Gynecol 2017 Mar 10. doi: 10.1002/uog.17447
  2. Tiralongo, G., Pisani, I., Vasapollo, B., Khalil, A., Thilaganathan, B. and Valensise, H. Nitric oxide (NO) donors and haemodynamic changes in fetal growth restriction. Ultrasound Obstet Gynecol 2017 doi:10.1002/uog.17454
  3. Uscom manufactures and markets the USCOM 1A, the Uscom BP+, and the Uscom SpiroSonic digital ultrasonic spirometry technologies. These premium digital devices are changing the way we diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD and sleep disorders. The products are integral for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, and in clinical and home care delivered asthma and COPD medications.

China BP+ and SpiroSonic Regulatory Submissions

March 22nd, 2017

China regulatory submission, distributor training and CIIC sales

Uscom has initiated China Food and Drug Administration (CFDA) submissions for approval to sell Uscom BP+ and Uscom SpiroSonic devices in China. CFDA approval is required before medical devices can be sold in China, and is valid for 5 years. The Uscom CFDA approval process is being managed by a specialist Beijing based regulatory consultant and overseen by Uscom Australia and our China Importation and wholesale partner, CIIC.

While the CFDA regulatory process is complex and of uncertain outcome and duration, both the BP+ and SpiroSonic product suites have current CE (European) regulatory approval and CFDA approved precedent devices, which may accelerate the approval timeline. The USCOM 1A has current CFDA approval, while this is the initial submission of the new Uscom BP+ and SpiroSonic devices.

China is an important market for Uscom, with much of it’s rapid revenue growth attributable to China sales of the USCOM 1A. The majority of current China sales have been derived from 5 distributors managed by Uscom’s Hong Kong based Asia Pacific distribution partners, Pacific Medical Systems. Uscom has recently increased it’s China activities and expanded its operations to include an additional partnership with a Shanghai based, Chinese state owned entity, CIIC Shanghai Science and Technology, and its distribution arm, Sense Medical. CIIC Shanghai Science and Technology will be responsible for the importation and wholesale of Uscom devices into China, while Sense Medical have been established to manage distribution of the Uscom devices into multiple Chinese provinces.
Uscom CEO Rob Phillips, Global Distribution Manager Denise Pater and Customer Relations Manager Bev Jacobson have just returned from initial training of 8 newly appointed distributors being managed by CIIC and Sense Medical. The training was accompanied by an order for 7 USCOM 1A devices.

Executive Chairman of Uscom, Associate Professor Rob Phillips said, “Success in China is very much a numbers and partners project. We have a state owned, Shanghai based importation and wholesale partner with growth aspirations beginning to feed our USCOM 1A into the 1.37B population Chinese market. The BP+ and SpiroSonic devices can then also be fed into these channels once we receive CFDA approvals. China has 32 provinces while we have previously only had 5 effective distributors. On this trip we trained 8 new CIIC appointed distributors covering previously un-served provinces, and further appointments are in process as we focus on onshore training and technical support. The new China importation and distribution model is planned to provide a platform for significantly increased distribution and revenue for the USCOM 1A, and then the new BP+ and SpiroSonic devices once they are approved for sale in China; this process is now underway.”

Uscom manufactures and markets the USCOM 1A, the Uscom BP+, and the Uscom SpiroSonic digital ultrasonic spirometry technologies. These premium digital medical devices are changing the way we diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD and sleep disorders. The products are integral for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, and in clinical and home care delivered asthma and COPD medications.

Uscom Receives $0.5M R&D Cash Refund

March 20th, 2017

Uscom has received $0.496M from the Australian Tax Office under the Federal Government Research and Development (R&D) Tax Incentive Program related to R&D expenditure in the 2016 tax year. The Federal Government R&D program provides for the refund of 45% of eligible research and development expenditure during the previous financial year.

Uscom has an on-going program of R&D planned to ensure that its current products are continually improved with new and innovative features, and new products conceived and developed for national and international markets. Uscom invests shareholder’s funds carefully, particularly in R&D, and recognises that while outcomes are uncertain, R&D is vital for the future of the Uscom business. The financial incentive offered by this Federal Government rebate is significant when Uscom plans the scale and objectives of its internal spending programs.

Executive Chairman of Uscom, Associate Professor Rob Phillips said, “Innovation is our business, and it’s both an Uscom corporate culture and a valuable investment for shareholders. The financial support offered by this Federal Government R&D program is vital for many Australian bioscience companies seeking advances in medical science where lead times can be significant. Research and development has many uncertainties, and this cash refund underwrites some of the risks for Australian companies and investors. The R&D tax incentive is a well-designed, targeted and administered program, creating a genuine encouragement for science companies to innovate and develop Australian employment, IP and export revenue, and Uscom is grateful for this support.”

Uscom manufactures and markets the USCOM 1A, the Uscom BP+, and the Uscom SpiroSonic digital ultrasonic spirometry technologies. These premium digital devices are changing the way we diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD and sleep disorders. The products are integral for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, and in clinical and home care delivered asthma and COPD medications.

New Uscom BP+ US Patent

March 6th, 2017

Applications in hypertension, heart failure and vascular Health

Uscom has received a Notice of Allowance from the United States Patent Office for a new method and apparatus patent related to its novel Uscom BP+ supra-systolic oscillometric central blood pressure monitor.

The patent describes a novel method and apparatus for producing a central pressure waveform in an oscillometric blood pressure system, and is central to the technology within the Uscom BP+ central blood pressure monitor. The patent was assigned the application number 15/224,821 and was filed on 1st August 2016, with a confirmation number 3711, and provides a 20 year period of commercial protection from the date of filing.

The patented technologies within Uscom BP+ improve the measurement of blood pressure, a fundamental clinical measurement of circulation, and represent some of the most advanced and innovative of cardiovascular technologies. The central pulse pressure wave measurements generated by the BP+ have application in the diagnosis and management of hypertension, heart failure and vascular health and have only previously been available using cardiac catheters. In children the device has been called the “non-invasive arterial line” for its potential to replace currently used arterial pressure catheters.
The BP+ measures central and brachial blood pressure and pulse pressure waves using supra-systolic oscillometry and is currently in regulatory review for approval for sale into China, Europe and the USA, with a number of new partnerships being negotiated for international distribution. By measuring directly into the aorta rather than measuring the arm BP, the Uscom BP+ provides potentially improved blood pressure monitoring measurements, and the devices has been invasively validated against catheters in children and adults.

Executive Chairman of Uscom, Associate Professor Rob Phillips said, “Patents are real value for shareholders and recognition of innovative and practice leading science. We see the Uscom BP+ and BP+ Reporter as the disrupting technologies for blood pressure, heart failure and critical care monitoring, and this new patent adds to the others in our BP+ suite. The BP+ is currently deployed on the International Space Station to provide novel insights into the cardiovascular physiology of astronauts. The Uscom BP+ has a real role in cardiovascular practice and we anticipate its adoption will grow rapidly once global approvals are granted over the next 12 months and as new specialist distributors are appointed.”

Uscom manufactures and markets the USCOM 1A, the Uscom BP+, and the Uscom SpiroSonic digital ultrasonic spirometry technologies. These premium digital devices are changing the way we diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD and sleep disorders. The products are integral for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, and in clinical and home care delivered asthma and COPD medications.

Uscom ends 2016 with record manufacturing

January 3rd, 2017

Uscom today notified the market that Uscom manufactured record numbers of USCOM 1A devices for the month of December 2016 and for the first half of FY 2017 to meet orders into Chinese, European and US clinical markets. In addition Uscom completed the manufacture of its 1,000th USCOM 1A cardiovascular monitor.

Manufacturing summary

Uscom manufactured a record number of USCOM 1A units for the month of December 2016, and in the second quarter of FY 2017. December quarterly manufacturing represented 42% of the total devices manufactured annually in FY 2016. The number of units manufactured in the first half of FY 2017 increased by 28% on the previous half and Uscom delivered its 1000th USCOM 1A device into global markets.

Uscom is anticipating the sequential commercial release of its new BP+ and BP+ Reporter and SpiroSonic series of devices and the accompanying SpiroReporter software into the Chinese, European and US markets over the next twelve months as regulatory permissions are received. CE approval for the SpiroSonic devices was received last month, with other approvals at various stages of preparation, submission and review. To date all revenue and revenue growth has predominantly been attributable to USCOM 1A sales.

Executive Chairman of Uscom, Associate Professor Rob Phillips said “Uscom is a milestone driven company, and despite complex global dynamics we are continuing our outstanding growth trends into the 5th consecutive year. We are currently preparing for the manufacture and sale of the BP+ and SpiroSonic series of devices into global markets as regulatory approvals are granted. This will involve transitioning to volume manufacturing to meet the current increased demand and the anticipated new demand; a change that will improve supply and margins. It’s really satisfying that our USCOM 1A device is now being adopted world wide in significant numbers to save the lives of children and adults, and remains an innovative cornerstone of advanced haemodynamics – we have effectively changed clinical practice. We anticipate the BP+ and SpiroSonic devices will do the same in complimentary clinical settings and start significantly contributing to revenue over the next 12 months.”

Uscom is the manufacturer of the USCOM 1A, the Uscom BP+, and Uscom SpiroSonic digital ultrasonic spirometry technologies. These premium digital devices are sold into global medical markets, changing the way clinician diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD and sleep disorders. The products are integral for optimising management of sepsis, guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, for advanced monitoring of hypertension and pre-eclampsia, and in clinical and home care asthma and COPD monitoring.